RSS-Feed abonnieren
DOI: 10.1055/s-0038-1660082
Urokinase Antigen in Plasma of Patients with Liver Cirrhosis and Hepatoma
Publikationsverlauf
Received 09. April 1985
Accepted 25. Juli 1985
Publikationsdatum:
19. Juli 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/198503/lookinside/thumbnails/10-1055-s-0038-1660082-1.jpg)
Summary
Plasma urokinase antigen levels were studied in 78 patients suffering from liver diseases. Blood was drawn before any specific medication was initiated. Impairment of liver function was comparable in all patients. In both groups of cirrhotic liver disease (alcoholic and non-alcoholic), normal levels of plasma urokinase antigen were found as compared to age-matched control groups. In both groups of patients with hepatomas (with or without a history of liver cirrhosis), however, significantly increased plasma urokinase antigen levels could be determined. These data indicate that an increase in plasma urokinase antigen might rather relate to malignant growth in liver disease than to impaired liver function.
-
References
- 1 Sherlock S. Diseases of the liver and biliary system (5th edition) Blackwell, London 1975
- 2 Goodpasture EW. Fibrinolysis in chronic hepatic insufficiency. Bull Johns Hopkins Hosp 1914; 25: 330-335
- 3 Finkbiner RB, McGovern JJ, Goldstein R, Bunker JR. Coagulation defects in liverdisease and response to transfusion during surgery. Am J Med 1959; 26: 199-204
- 4 Grossi CE, Moreno AH, Rousselot LM. Studies on spontaneous fibrinolytic activity in patients with cirrhosis of the liver and itsinhibition by epsilon amino capronic acid. Ann Surg 1961; 153: 383-393
- 5 Grossi CE, Rousselot LM, Pauke WF. Coagulation defects in patients with cirrhosis of the liver undergoing portasystemic shunts. Am J Surg 1962; 104: 512-516
- 6 Fletcher AP, Biederman O, Moore D, Alkjaersig N, Sherry S. Abnormal plasminogen-plasminsystem activity in patients withhepatic cirrhosis: its cause andconsequences. J Clin Invest 1964; 43: 681-695
- 7 Kwaan HC, McFadsean AJS, Cook I. Plasma fibrinolytic activity in cirrhosis of the liver. Lancet 1956; 1: 132-136
- 8 Matsuo O, Kosugi T, Mihara H. Urokinase inactivation rate in the rabbit: effect of circulatory isolation of the liver, spleen and kidneys. Haemostasis 1978; 7: 367-372
- 9 Korninger C, Stassen JM, Collen D. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. Thromb Haemostas 1981; 46: 658-661
- 10 Booth NA, Anderson JA, Bennett B. Plasminogen activators in alcoholic cirrhosis: demonstrationof increased tissue type and urokinase type activator. J Clin Pathol 1984; 37: 772-777
- 11 Huber K, Kirchheimer J, Binder BR. Characterization of a specific anti-human urokinase antibody: development of a sensitive competition radioimmunoassay for urokinase antigen. J Lab Clin Med 1984; 103: 684-694
- 12 Huber K, Kirchheimer J, Binder BR. Urokinase-type plasminogen activator in some gastrointestinal diseases - application of a specific radioimmunoassay for urokinase antigen. In: Clinical Aspects of Fibrinolysis and Thrombolysis Jespersen J, Kluft C, Korsgaard O. (eds.) Esbjerg: South Jutland University Press; 1983: 71-82
- 13 Kirchheimer J, Binder BR. Urokinase antigen in plasma:age and sex dependent variations. Thromb Res 1984; 36: 643-646
- 14 Gelehrter TD, Baronski-Miller PA, Coleman PL, Cwikel BJ. Hormonal regulation of plasminogen activator in rat hepatomacells. Mol Cell Biol 1983; 53/54: 11-21
- 15 Sherman LA, Lee JL, Stewart CC. Release of fibrinolytic enzymes by macrophages in response to soluble fibrin. J Reticuloendothel Soc 1981; 30: 317-329
- 16 Vasalli JD, Hamilton J, Reich E. Macrophage plasminogen activator: modulation of enzyme production by anti-inflammatory steroids, mitotic inhibitors and cyclic nucleotides. Cell 1976; 8: 271-281
- 17 Kirchheimer JC, Pfluger H, Hienert G, Binder BR. Increased urokinase activityto antigen ratio in human renal cell carcinoma. Int J Cancer 1985; 35: 737-741
- 18 Korninger C, Wagner O, Binder BR. Tissue plasminogen activatorinhibitor (antiactivator) in human plasma: Development of a functional assay system and demonstration of a correlating Mr = 50000 antiactivator. J Lab Clin Med 1985; 105: 718-724